Provectus Biopharmaceuticals

(OTC) PVCT

Current Price$0.06

Market Cap$25.47M

Since IPO (2002)-94%

5 Year-12%

1 Year-21%

1 Month-12%

Provectus Biopharmaceuticals Financials at a Glance

Market Cap

$25.47M

Revenue (TTM)

$57.48K

Net Income (TTM)

-$5.62M

EPS (TTM)

-$0.01

P/E Ratio

-4.56

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Price

$0.06

Volume

155,363

Open

$0.06

Price

$0.06

Volume

155,363

Open

$0.06

Previous Close

$0.06

Daily Range

$0.06 - $0.07

52-Week Range

$0.04 - $0.11

Estimated Earnings Date

May 13, 2026

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Price

$0.06

Volume

155,363

Open

$0.06

Previous Close

$0.06

Daily Range

$0.06 - $0.07

52-Week Range

$0.04 - $0.11

Estimated Earnings Date

May 13, 2026

PVCT News

This Week in Biotech: PTC Therapeutics Surprises, Isis' Data Dazzles, and Provectus Sinks

Sean WilliamsMay 24, 2014

Why Provectus Biopharmaceuticals Inc. Shares Plummeted

Sean WilliamsMay 22, 2014

3 Humongous Health-Care Stocks This Week

Keith SpeightsDec 28, 2013

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Provectus Biopharmaceuticals

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Edward V. Pershing, CPA

Website

www.provectusbio.com

Headquarters

Knoxville, TN 37932, US

PVCT Financials

Key Financial Metrics (TTM)

Gross Margin

97%

Operating Margin

-89%

Net Income Margin

-98%

Return on Equity

Return on Capital

76%

Return on Assets

-10%

Earnings Yield

-21.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.47M

Shares Outstanding

420.28M

Volume

155.36K

Avg. Volume

215.54K

Financials (TTM)

Gross Profit

$334.25K

Operating Income

-$4.84M

EBITDA

-$4.84M

Operating Cash Flow

-$3.33M

Capital Expenditure

$0.00

Free Cash Flow

-$3.33M

Cash & ST Invst.

$251.29K

Total Debt

$2.98M

Provectus Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$466.00

+99.5%

Gross Margin

0.00%

N/A

Market Cap

$25.47M

N/A

Market Cap/Employee

$4.24M

N/A

Employees

N/A

Net Income

-$1.29M

-13.2%

EBITDA

-$1.10M

-0.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$223.88K

-42.7%

Total Debt

$2.77M

+7.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$66.65K

N/A

Short Term Debt

$2.70M

+4.8%

Return on Assets

-9.73%

N/A

Return on Invested Capital

76.48%

N/A

Free Cash Flow

-$357.57K

+67.3%

Operating Cash Flow

-$357.57K

+67.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MBXBFMicrobix Biosystems Inc.

MBXBFMicrobix Biosystems Inc.$0.19+0.00%

DTCFFDefence Therapeutics Inc.

DTCFFDefence Therapeutics Inc.$0.39+5.78%

SEOVFSernova Corp.

SEOVFSernova Corp.$0.11+0.00%

CLYYFCelyad Oncology S.A.

CLYYFCelyad Oncology S.A.$0.25+0.00%

MMIRFMedMira Inc.

MMIRFMedMira Inc.$0.01+0.00%

WOWUWOWI, Inc.

WOWUWOWI, Inc.$0.00+0.00%

BBIXFBonus BioGroup Ltd.

BBIXFBonus BioGroup Ltd.$0.13+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$160.95+0.19%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

NOKNokia

NOKNokia$14.80+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

TSLATesla

TSLATesla$406.43+0.02%

Questions About PVCT

What is the current price of Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals is trading at $0.06 per share.

What is the 52-week range for Provectus Biopharmaceuticals?

Over the past 52 weeks, Provectus Biopharmaceuticals has traded between $0.04 and $0.11.

How much debt does Provectus Biopharmaceuticals have?

As of the most recent reporting period, Provectus Biopharmaceuticals reported total debt of $2.77M.

How much cash does Provectus Biopharmaceuticals have on hand?

Provectus Biopharmaceuticals reported $223.88K in cash and cash equivalents in its most recent financial results.

What is Provectus Biopharmaceuticals’s dividend yield?

Provectus Biopharmaceuticals does not currently have a dividend yield.

Provectus Biopharmaceuticals

Provectus Biopharmaceuticals Financials at a Glance

PVCT News

Shorts Are Piling Into These Stocks. Should You Be Worried?

3 Stocks Crushed by the Market Last Week

63% Implosion: The Epic Collapse of Provectus Biopharmaceuticals, Inc

5 of Last Week's Biggest Losers

This Week in Biotech: PTC Therapeutics Surprises, Isis' Data Dazzles, and Provectus Sinks

Why Provectus Biopharmaceuticals Inc. Shares Plummeted

3 Humongous Health-Care Stocks This Week

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Provectus Biopharmaceuticals

PVCT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Provectus Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PVCT

What is the current price of Provectus Biopharmaceuticals?

What is the 52-week range for Provectus Biopharmaceuticals?

How much debt does Provectus Biopharmaceuticals have?

How much cash does Provectus Biopharmaceuticals have on hand?

What is Provectus Biopharmaceuticals’s dividend yield?

Premium Investing Services